Tenax Therapeutics, Inc. and Michael B. Jebsen, the company's President agreed that Mr. Jebsen would separate from the company effective October 29, 2021. As of the Separation Date, the company’s current Chief Executive Officer and principal executive officer, Christopher T. Giordano, will assume the additional position of President of the company. Pursuant to the Danforth Consulting Agreement, Mr. Lurier will be responsible for the company’s accounting and finance functions and will serve as the company’s principal financial officer and principal accounting officer beginning on the Separation Date. Mr. Lurier will provide services to the company under the Danforth Consulting Agreement as an independent contractor.